Table 1.
Baseline Characteristics and number of patients on low, medium, and high Sacubitril/Valsartan dose
| Sacubitril/Valsartan (n=48) (± SD or 25th-75th quartile IQR) | |
|---|---|
| Mean age (Years) | 70 (±11.1) |
| Median NYHA (IQR) | 2 (2.0-2.5) |
| Mean systolic BP mmHg | 114 (±16.7) |
| Mean baseline creatinine (umol/L) | 93.4 (±21.8) |
| Mean baseline potassium level (mmol/L) | 4.25 (±0.42) |
| Mean pre-baseline ejection fraction | 26.91% (±8.9) |
| Mean baseline ejection fraction | 26.41% (±7.7) |
| Female (%) | 10 (20.8%) |
| Non-ischemic etiology for HF (%) | 25 (53.2%) |
| Hypertension (%) | 23 (47%) |
| Diabetes (%) | 13 (27%) |
| Hyperlipidemia (%) | 22 (45.8%) |
| History of atrial fibrillation (%) | 7 (14.6%) |
| Previous CVA (%) | 3 (6.3%) |
| Medications at baseline | |
| On a Beta Blocker (%) | 47 (97.9%) |
| Sacubitril/Valsartan Dose | |
| Low dose (24.3/25.7 mg) | 10 (23.8%) |
| Medium dose (49/51 mg) | 9 (21.4%) |
| High dose (97.2/102.8 mg) | (54.8%) |